Everything drug pricing and policy, every day
And Lilly’s earnings call details a fundamental fact of the market: drug prices generally go down over time
And two companies push back on a 340B loophole that allows for-profit doctors access to 340B prices
Plus STAT goes deep on Bausch Health’s decision to leave Medicaid/340B and more commentary on the Cigna/Express Scripts rebate announcement
And earnings season is upon us, though CEO commentary on policy issues -- thus far -- remains scant
And the media attention around 2026 premium increases is only growing
And five illuminating images from this week’s KFF survey on employer-sponsored insurance
And introducing an Apex-only resource on "Team MFN": the four administration officials who are spearheading negotiations for the White House's company-by-company drug pricing push
And a new entrant into the “direct-to-business” space promises employers more flexibility in drug coverage ... and a path around PBMs
And lost rebates from 340B in Medicare are costing that program $13 billion
